News 
Market Data 
Discover
| Followers | 80 |
| Posts | 3,532 |
| Boards Moderated | 0 |
| Alias Born | 06/04/2012 |
| Twitter Profile: | Temporarily Unavailable |
| Follow on Twitter: | Follow @ Temporarily Unavailable |
High_Profits
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yup GURU Nailed it But ....
U Forgot our FDA Registered Laboratory
VIDEO =
here is what changed today at OTC
PRED is not longer considered a Penny Stock
https://www.otcmarkets.com/stock/PRED/profile
Penny Stock Exempt
This security is exempt from the definition of a Penny Stock under SEC under Rule 240.3a51-1 because it meets one of the following tests: 1) A price of over $5 per share, 2) the issuer has Average Revenue of at least $6 million for the last 3 years, or 3) the issuer has Net Tangible Assets in excess of $2 million if the issuer has been in continuous operations for at least 3 years or $5 million if less than 3 years.
Subscribe to PRED on YouTube for next Videos
https://www.youtube.com/channel/UCak35geV4BLmji1xRhdzpZg
OTC updated all info Including PRED Chairman John Sorrentino from Pfizer
https://www.otcmarkets.com/stock/PRED/profile
OTC UPGRADE & NASDAQ STILL PENDING
https://finance.yahoo.com/news/predictive-technologies-group-pred-upgrades-110005959.html
NASDAQ Still Under Review....
“We are pleased to be accepted to trade on the OTCQX Best Market. Our previously announced listing application for the NASDAQ Market exchange is currently in the review process,” Mr. Robinson concluded
New IR / PR Team
LifeSci Public Relations / Advisors
http://www.lifescipublicrelations.com
and
https://www.lifesciadvisors.com
Incredible post
Thanks for sharing
Interesting timing for the rollout 
Agree TKT - Ignore the Noise focus on the fundamentals
Amazing New PRED Professional Video - cant wait to see the others
https://vimeo.com/367355547 - password time sensitive [starwars]
Beautiful - Bring it on !!
This article indicates FDA wants to ensure the highest standards and safety for Regenerative Medicine and Gene Therapy going forward
https://www.pewtrusts.org/en/research-and-analysis/reports/2019/10/17/fdas-framework-for-regulating-regenerative-medicine-will-improve-oversight
everyone see Hindenberg Research was Highlighted on CNBC -
Never Seen that before wonder if CNBC is on on the Short Action
Alert to Short Smile Direct / SDC
Amazing they continue to flourish hurting Valuations of Public Companies like PRED
Thanks Brad for your Leadership in bringing Predictive to China !!!
http://predtechgroup.com/2019/10/predictive-technology-group-engages-clsa-capital-markets-limited-a-citic-securities-company-to-support-product-launches-into-chinas-rapidly-growing-womens-health-and-fertility-mark/
Who the Heck is Citic Bank and CLSA - see below ..............
Its gonna be cool to see how this all develops
CITIC BANK https://en.wikipedia.org/wiki/CITIC_Group
CITIC Group Corporation Ltd., formerly the China International Trust Investment Corporation, is a state-owned investment company of the People's Republic of China, established by Rong Yiren in 1979 with the approval of Deng Xiaoping.[2] Its headquarters are in Chaoyang District, Beijing.[3] As of 2019,
it is China's biggest state-run conglomerate with one of the largest pools of foreign assets in the world
[Ranked #41 on Worlds Largest Bank List]
Ranked with GOLDMAN SACHS and MORGAN STANLEY
= It's China's biggest state-run conglomerate with one of the largest pools of foreign assets in the WORLD !!
TOP WORLD BANK Rankings = CITIC #41
https://www.relbanks.com/worlds-top-banks/assets
CITIC Investment Bank Division = "CLSA" or Credit Lyonnais Securities Asia
https://www.clsa.com/services/corporate-finance/
CITIC / China's largest investment bank acquired CLSA for US$ 1.3 billion.
https://en.wikipedia.org/wiki/CLSA
Stunning NEW $ELGL Website
https://elementglobal.com/
Great Details within all Subsidiaries
https://elementglobal.com/subsidiaries/
CITIC Medical & Health Group / Operate Many State Run Hospitals and Medical Facilities / Article
https://asia.nikkei.com/Business/Itochu-aims-to-operate-Chinese-hospitals-with-Citic
CITIC Medical and Healthcare Group is involved in healthcare, senior citizen care, health management, pharmaceutical distribution, etc. CITIC-Xiangya Reproductive & Genetic Hospital is the leading center of the world in terms of IVF (in vitro fertilization) and pregnancy rate.
Who are CLSA & CITIC Bank? = PRED's Financing Partner?
CITIC and CLSA are Absoutely MASSIVE !!!
CITIC BANK https://en.wikipedia.org/wiki/CITIC_Group
CITIC Group Corporation Ltd., formerly the China International Trust Investment Corporation, is a state-owned investment company of the People's Republic of China, established by Rong Yiren in 1979 with the approval of Deng Xiaoping.[2] Its headquarters are in Chaoyang District, Beijing.[3] As of 2019,
it is China's biggest state-run conglomerate with one of the largest pools of foreign assets in the world
[Ranked #41 on Worlds Largest Bank List]
Ranked with GOLDMAN SACHS and MORGAN STANLEY
= It's China's biggest state-run conglomerate with one of the largest pools of foreign assets in the WORLD !!
TOP WORLD BANK Rankings = CITIC #41
https://www.relbanks.com/worlds-top-banks/assets
CITIC Investment Bank Division = "CLSA" or Credit Lyonnais Securities Asia
https://www.clsa.com/services/corporate-finance/
CITIC / China's largest investment bank acquired CLSA for US$ 1.3 billion.
https://en.wikipedia.org/wiki/CLSA
$PRED NEWS Predictive & CLSA / CITIC BANK of China
https://finance.yahoo.com/news/predictive-technology-group-engages-clsa-130000670.html
Predictive Technology Group Engages CLSA Capital Markets Ltd a CITIC Securities Company to Support Product Launches into China's Rapidly Growing Women's Health and Fertility Market
ALT LAKE CITY , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, announces that it has engaged CLSA Capital Markets Limited , a CITIC Securities Company , to provide introductions to potential strategic partners and regulatory guidance to support the launch of its proprietary genetic-based products into China’s (PRC) rapidly growing markets for women’s health and fertility. Terms of the transaction were not disclosed.
“Given our genetic library, research and understanding of genetics, endometriosis and other factors that may affect a woman’s fertility, we are excited to bring our noninvasive testing technology to this large, emerging market that already surpasses the U.S. in terms of the number of affected women,” said Bradley Robinson , Chief Executive Officer of Predictive Technology Group . “Our tests help both the doctor and patient understand and navigate the barriers to fertility, changing the path to a healthy baby. We are especially pleased to collaborate in this endeavor with CLSA, a leading capital markets and investment group in Asia.”
https://www.clsa.com/services/corporate-finance/
Predictive expects to introduce ARTguide™ among other fertility diagnostics to the Chinese market. On October 14, 2019 , Predictive launched the full U.S. market availability of ARTguide, its test to evaluate the risk for endometriosis and other genetic causes of infertility in women, at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo in Philadelphia .
In 2016 the National Health and Family Planning Commission of the PRC reported that 40 million Chinese couples were experiencing fertility issues. Similarly, the American Society for Reproductive Medicine (ASRM) reported in 2017 that an estimated 25% of Chinese women of childbearing age struggled with infertility issues. In 2018 the European Society of Human Reproduction and Embryology estimated that approximately 800,000 assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF), were being performed in China annually. Chinese women are driving the fertility markets both in China and medical tourism industries overseas. The global IVF market is expected to grow at an annual rate of 10.2% and to reach $36.2 billion by 2026. The U.S. Center for Disease Control reported that of the patients who sought fertility care in 2017, 284,385 ART cycles were performed resulting in 78,052 live born infants with ART accounting for 1.7% of all infants born in the U.S. annually.
Predictive Laboratories ARTguide Test ARTguide is the first integrated, DNA-based test that evaluates the risk for endometriosis and other genetic causes of infertility in women. It provides a greater understanding of over a dozen genetic conditions affecting a woman’s fertility by identifying previously invisible barriers to conception, consequently improving ART success rates. ARTguide is appropriate for all women considering use of ART to overcome difficulty conceiving or carrying a pregnancy.
ARTguide was introduced to a limited number of U.S. clinics in 2018. Predictive Laboratories is a wholly owned molecular and genetic diagnostics company of Predictive Technology Group focused on hard-to-detect diseases, women’s health and infertility. Predictive Laboratories recently completed a laboratory expansion to add capacity that allows ARTguide to be available more broadly in the U.S.
Endometriosis
is an estrogen-responsive, chronic condition that arises from extra-uterine growth of the stromal or glandular tissue that line the uterus. Often called the “invisible disease,” endometriosis affects an estimated 1 in 10 women in the U.S. during their reproductive years with many cases go undiagnosed. It is common for a woman to experience symptoms—such as chronic pelvic pain, heavy or painful periods—for a decade or more before a diagnosis is made (13 years, on average, in China ). The current standard for diagnosis is laparoscopic surgery, to biopsy lesions found within the fallopian tubes or uterus. Even with this surgery, intraoperative diagnosis by conventional laparoscopic visualization is frequently difficult and inaccurate.
Severe endometriosis with extensive scarring and organ damage is one of the most common causes of female infertility. However, endometriosis can still affect fertility when no symptoms are present. 30% to 50% of women with endometriosis may experience infertility, and 25% to 50% of women who experience infertility have endometriosis.
Studies have linked the risk of endometriosis to ethnicity, with several reporting Asian women’s risk being nine times greater than that of Caucasian women. A recent systematic review analyzing the outcomes of more than 1.9 million Chinese women found endometriosis to be associated with the worsening of obstetric and pregnancy-related outcomes, including miscarriage, pre-term labor, placenta previa, small for gestational age, and caesarean delivery compared to healthy controls.
Predictive Laboratories, Inc. Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis. For more information, visit http://www.predictivelabs.com.
Predictive Technology Group, Inc. Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories , Predictive Biotech and Predictive Therapeutics. For more information, visit http://www.predtechgroup.com.
CLSA Capital Markets Limited CLSA is Asia’s leading capital markets and investment group, providing global investors with insights, liquidity, and capital to drive their investment strategies. Award-winning research, an extensive Asia footprint, direct links to China , and highly experienced finance professionals differentiate our innovative products and services in asset management, corporate finance, capital, and debt markets, securities, and wealth management. As the international platform of CITIC Securities (SSE: 600030, SEHK: 6030), China’s largest investment bank, CLSA is uniquely positioned to facilitate cross-border capital flows and connect China with the world and the world to China . Founded in 1986 and headquartered in Hong Kong , CLSA’s global network spans 21 locations across Asia , Australia , Europe , and the United States . For more information, visit http://www.clsa.com. ;
Forward-Looking Statements To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts For more information, visit www.predtechgroup.com or contact Investor Relations:
Media Contact Holly Dugan predictive@antennagroup.com 201-465-8019
Investor Contact LHA Investor Relations Jody Cain jcain@lhai.com Kevin Mc Cabe kmccabe@lhai.com 310-691-7100
PRED NEWS - Predictive Labs Launches FertilityDX
https://finance.yahoo.com/news/predictive-laboratories-launches-fertilitydx-120000074.html
Predictive Laboratories Launches FertilityDX™
https://www.predictivelabs.com/fertilitydx
GlobeNewswire•October 14, 2019
Genetic testing service now available to identify causes of infertility and guide personalized fertility treatments
SALT LAKE CITY, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces the launch of FertilityDX™, a comprehensive genetic testing service that identifies barriers to healthy pregnancy and birth, allowing doctors to tailor fertility treatments. The test launch will be formally announced at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo, Oct. 12-16 in Philadelphia.
“For the one in eight couples who struggle with infertility, trying to have a child can be financially, physically and emotionally exhausting—largely because the couple doesn’t know why they are having difficulty conceiving,” said Kenneth Ward, M.D., Laboratory Director of Predictive Laboratories. Dr. Ward is a board-certified physician in obstetrics and gynecology, perinatology, clinical genetics and molecular genetics. “Our desire is to arm couples considering assisted reproductive technologies (ART) with an understanding of the genetic and medical obstacles that may be affecting their fertility and provide doctors with genetically relevant information to help their patients have a healthy baby.”
FertilityDX provides information by evaluating three key areas: contributors to (or causes of) infertility, risks of pregnancy complications, and risks for serious genetic conditions in offspring.
FertilityDX supports both physician and patient throughout the entirety of the treatment process. Patients are provided with pretest counseling and clear and relevant test results. Physicians get an easy-to-understand final report and access to a variety of genetics consultants. The test will be launched in select fertility clinics across the United States, offering couples access to the most comprehensive genetic service to date.
About Predictive Laboratories
Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis.
The Company’s proprietary tests include ARTguideTM and FertilityDXTM. ARTguide is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDX is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visit http://www.predictivelabs.com. http://predrx.com/
LinkedIn now Shows 60 Pred Bio Tech - up 5 this wk
started the week at 55 employed
https://www.linkedin.com/company/predictive-biotech-inc/
Only 1 Day Away - American Society for Reproductive Medicine (ASRM) $PRED
https://asrmcongress.org/
9,300 Registered / 94 Countries
PRED to Present at ASRM
https://finance.yahoo.com/news/predictive-technology-group-reports-fiscal-200200794.html
ARTguide’s full market availability will be announced during the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo, Oct. 12 - 16 in Philadelphia. In addition to sharing this news, Dr. Ward, a board-certified physician in obstetrics and gynecology, perinatology, clinical genetics and molecular genetics, will present two scientific papers at ASRM. The schedule of his speaking engagements are as follows:
Wednesday, Oct. 16 at 6:30 a.m. ET — Poster presentation: Endometriosis risk allele in WNT4 may interact with rare mutations in HDAC2 gene
Wednesday, Oct. 16 at 11:15 a.m. ET — Oral abstract: Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk
Dr. Ward’s colleague, Hans Albertsen, Ph.D., will present additional endometriosis data on Wednesday, Oct. 16 at 11:30 a.m. ET — Oral abstract: Cytoskeletal and extracellular matrix genes are key contributors in the pathogenesis of endometriosis.
Amazing ArtGuide Numbers - thanks Thomas for your estimates
ARTguide™ Market:
The market revenue from ARTguide™ is rather simple (remember there are 24 million endometriosis symptomatic undiagnosed women in the U.S.) and the below data does not include Preeclampsia, ART (IVF), and many other indications;
Survey data indicates all fertility clinics are interested in ARTguide™;
A significant percentage (35 to 40%) of those clinics will order the ARTguide™ test for new patients;
And new and existing female patients equal an average of 35 prescriptions per month per doctor.
Initially, 15 larger clinics for clinical research are interested, and;
Assume 12 (of the 15 clinics), each with 9 doctors will produce $150 million in annual revenue from the ARTguide™ diagnostic;
Now consider 200 infertility doctors in the U.S. prescribing 35 prescriptions per month, which generates over $3.3 billion in yearly revenue.
There are 480+ female reproduction and fertility doctors identified (highly confident) that will use ARTguide™ in the U.S.
ENDOMETRIOSIS:
The 2019 American Society for Reproductive Medicine (ASRM) will be attended by 9,300 reproductive doctors, specialists, and scientists, from 94 countries, representing a diagnosed endometriosis population of 176 million, and an estimated undiagnosed population of another 128 million women (for those that have been paying attention, China has 74+ million women diagnosed with endometriosis).
PREECLAMPSIA:
Preeclampsia affects 5-8%, or approximately 300,000, pregnancies every year in the United States, and approximately 1.25 million pregnancies in China, causing severe adverse maternal and fetal outcomes, including significant blood loss, organ failure, disability or even death. Globally, preeclampsia is a leading cause of pregnancy complications, preterm births, and related disabilities. The deaths of approximately 76,000 mothers and 500,000 babies annually worldwide are attributable to preeclampsia. [url]Imprecise diagnostic tools hamper healthcare providers, even in medically advanced countries.
Consider PRED's U.S. and internationally patented ARTguide™ diagnostic is now launched at the world's leading reproductive conference (ASRM) attended by over 9,300 reproductive specialists, representing a global diagnosed and undiagnosed endometriosis population of 300+ million women.
the Figures above DO NOT Include foreign markets like China so assume 3x those figures once added and implemented
and Japan has the highest endometriosis per capita of all Asian populations - next stop Tokyo, India, etc. per Thomas
Only 2 Days Away - American Society for Reproductive Medicine (ASRM) $PRED
https://asrmcongress.org/
9,300 Registered / 94 Countries
The premier education and research meeting for Reproductive Medicine
Scientific sessions, Pre-Congress courses, and video programs presented by experts
New PRED Public Relations / MEDIA Firm = Antenna Group
Clinets include Pfizer & many BioTech / Healthcare Companies
https://www.antennagroup.com/results/clients
Media Contact:
Holly Dugan
predictive@antennagroup.com
201-465-8019
Twitter
https://twitter.com/antenna_group
FaceBook
https://www.facebook.com/antennagroup/
https://finance.yahoo.com/news/predictive-laboratories-announces-commercialization-full-120000192.html
PRED ARTguide - Description
Predictive Laboratories Announces Commercialization And Full Market Availability Of ARTguide(TM)
https://www.marketwatch.com/press-release/predictive-laboratories-announces-commercialization-and-full-market-availability-of-artguidetm-at-american-society-of-reproductive-medicine-asrm-scientific-congress-and-expo-2019-10-10-8184135
PRED Changes Company Description
Changed to ...
Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility
Was
PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies
https://finance.yahoo.com/news/predictive-technology-group-reports-fiscal-200200794.html
Predictive Laboratories Announces Commercialization And Full Market Availability Of ARTguide™ At American Society Of Reproductive Medicine (ASRM) Scientific Congress And Expo
CNBC's Pete Najarian disclosed Long Stock Pics on CNBC include PRED
https://www.cnbc.com/pete-najarian/
Long stock Disclosure: 3M, Apple, Bank of America, Canada Goose, Casey’s General Stores, CitiGroup, The Coca-Cola Co, CryoPort Inc, ExxonMobil, Facebook, H.B.Fuller, IBM, Intel, Kinder Morgan, Las Vegas Sands, Luckin Coffee, Lululemon Athletica, Marathon Petroleum, Merck & Co., Micron Technology, Microsoft, Netflix, PepsiCo, Pfizer, Predictive Technology Group
Nice company we keep
